Duloxetine in the treatment of major depressive disorder: Comparisons of safety and tolerability in male and female patients

Journal of Affective Disorders

Volumn 94, Issue 1-3, 2006, Pages 183-189

  Stewart, Donna E ^a   Wohlreich, Madelaine M ^b   Mallinckrodt, Craig H ^b   Watkin, John G ^b   Kornstein, Susan G ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b ELI LILLY AND COMPANY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Duloxetine; Female; Major depressive disorder; Male; Safety

Indexed keywords

DULOXETINE; PLACEBO;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE FLUCTUATION; CONSTIPATION; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMERGENCY TREATMENT; ERECTILE DYSFUNCTION; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; PRIORITY JOURNAL; PULSE RATE; SEX DIFFERENCE; SIDE EFFECT; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; META-ANALYSIS; META-ANALYSIS AS TOPIC; MIDDLE AGED; MULTICENTER STUDIES; MULTICENTER STUDIES AS TOPIC; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; THIOPHENES;

EID: 33746253361     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2006.04.006     Document Type: Article

References (33)

1. Abernethy D.R., Greenblatt D.J., and Shader R.I. Imipramine disposition in users of oral contraceptive steroids. Clin. Pharmacol. Ther. 35 (1984) 792-797
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition (1994), APA, Washington, DC
3. Brannan S.K., Mallinckrodt C.H., Brown E.B., Wohlreich M.M., Watkin J.G., and Schatzberg A.F. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J. Psychiatr. Res. 39 (2005) 43-53
4. Casper R.C., Tollefson G.D., and Nilsson M.E. No gender differences in placebo responses of patients with major depressive disorder. Biol. Psychiatry 49 (2001) 158-160
5. Dahl M.L., Bertilsson L., and Nordin C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology (Berl.) 123 (1996) 315-319
6. Delgado P.L., Brannan S.K., Mallinckrodt C.H., Tran P.V., McNamara R.K., Wang F., Watkin J.G., and Detke M.J. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J. Clin. Psychiatry 66 (2005) 686-692
7. Detke M.J., Lu Y., Goldstein D.J., Hayes J.R., and Demitrack M.A. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J. Clin. Psychiatry 63 (2002) 308-315
8. Detke M.J., Lu Y., Goldstein D.J., McNamara R.K., and Demitrack M.A. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J. Psychiatr. Res. 36 (2002) 383-390
9. Drici M.D., and Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Safety 24 (2001) 575-585
10. Entsuah A.R., Huang H., and Thase M.E. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J. Clin. Psychiatry 62 (2001) 869-877
11. Fattinger K., Roos M., Vergeres P., Holenstein C., Kind B., Masche U., Stocker D.N., Braunschweig S., Kullak-Ublick G.A., Galeazzi R.L., Follath F., Gasser T., and Meier P.J. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br. J. Clin. Pharmacol. 49 (2000) 158-167
12. Frackiewicz E.J., Sramek J.J., and Cutler N.R. Gender differences in depression and antidepressant pharmacokinetics and adverse events. Ann. Pharmacother. 34 (2000) 80-88
13. Gex-Fabry M., Balant-Gorgia A.E., Balant L.P., and Garrone G. Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data. Clin. Pharmacokinet. 19 (1990) 241-255
14. Goldstein D.J., Mallinckrodt C., Lu Y., and Demitrack M.A. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J. Clin. Psychiatry 63 (2002) 225-231
15. Goldstein D.J., Lu Y., Detke M.J., Wiltse C., Mallinckrodt C., and Demitrack M.A. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J. Clin. Psychopharmacol. 24 (2004) 389-399
16. Greenblatt D.J., Friedman H., Burstein E.S., Scavone J.M., Blyden G.T., Ochs H.R., Miller L.G., Harmatz J.S., and Shader R.I. Trazodone kinetics: effect of age, gender, and obesity. Clin. Pharmacol. Ther. 42 (1987) 193-200
17. Guentert T.W., Banken L., Hilton S., and Holford N.H. Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events. J. Clin. Psychopharmacol. 15 (1995) 84S-94S
18. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised 1976 (1976), National Institutes of Mental Health, Rockville, MD
19. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
20. Harris R.Z., Benet L.Z., and Schwartz J.B. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50 (1995) 222-239
21. Hildebrandt M.G., Steyerberg E.W., Stage K.B., Passchier J., and Kragh-Soerensen P. Are gender differences important for the clinical effects of antidepressants?. Am. J. Psychiatry 160 (2003) 1643-1650
22. Joyce P.R., Mulder R.T., Luty S.E., Sullivan P.F., McKenzie J.M., Abbott R.M., and Stevens I.F. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust. N. Z. J. Psychiatry 36 (2002) 384-391
23. Kornstein S.G., and McEnany G. Enhancing pharmacologic effects in the treatment of depression in women. J. Clin. Psychiatry 61 Suppl. 11 (2000) 18-27
24. Kornstein S.G., and Wojcik B.A. Gender effects in the treatment of depression. Psychiatr. Clin. N. Am. Ann. Drug Ther. 7 (2000) 23-57
25. Kornstein S.G., Schatzberg A.F., Thase M.E., Yonkers K.A., McCullough J.P., Keitner G.I., Gelenberg A.J., Davis S.M., Harrison W.M., and Keller M.B. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am. J. Psychiatry 157 (2000) 1445-1452
26. Nemeroff C.B., Schatzberg A.F., Goldstein D.J., Detke M.J., Mallinckrodt C., Lu Y., and Tran P.V. Duloxetine for the treatment of major depressive disorder. Psychopharmacol. Bull. 36 (2002) 106-132
27. Raskin J., Goldstein D.J., Mallinckrodt C.H., and Ferguson M.B. Duloxetine in the long-term treatment of major depressive disorder. J. Clin. Psychiatry 64 (2003) 1237-1244
28. Sharma A., Goldberg M.J., and Cerimele B.J. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J. Clin. Pharmacol. 40 (2000) 161-167
29. Skinner M.H., Kuan H.Y., Pan A., Sathirakul K., Knadler M.P., Gonzales C.R., Yeo K.P., Reddy S., Lim M., Ayan-Oshodi M., and Wise S.D. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin. Pharmacol. Ther. 73 (2003) 170-177
30. Stewart D.E. Are there special considerations in the prescription of serotonin reuptake inhibitors for women?. Can. J. Psychiatry 43 (1998) 900-904
31. Thase M.E., Tran P.V., Wiltse C., Pangallo B.A., Mallinckrodt C.H., and Detke M.J. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J. Clin. Pharmacol. 25 (2005) 132-140
32. Tran C., Knowles S.R., Liu B.A., and Shear N.H. Gender differences in adverse drug reactions. J. Clin. Pharmacol. 38 (1998) 1003-1009
33. Yonkers K.A., Kando J.C., Cole J.O., and Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am. J. Psychiatry 149 (1992) 587-595